DSGN - Company ID 0001807120
Design Therapeutics, Inc. trades as DSGN. In its fiscal 2025 annual report the company posted revenue of $0.00 and net income of -$69.79M. This page tracks Design Therapeutics, Inc. through 252 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-18 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-04-28 |
| Major company event | 8-K | 2026-04-28 |
| Proxy materials | DEFA14A | 2026-04-23 |
| Proxy statement | DEF 14A | 2026-04-23 |
| Annual report to shareholders | ARS | 2026-04-23 |
| Insider trade | 4 | 2026-04-01 |
The largest companies sharing Design Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Design Therapeutics, Inc. reported revenue of $0.00 for fiscal year 2025.
In its latest fiscal year Design Therapeutics, Inc. reported a net loss of $69.79M.